Remission & chronicity

Spontaneous remission

Chronic and progressive; glandular dysfunction (dry eyes/mouth) irreversible in most; fatigue and systemic features fluctuate; lymphoma risk 5-15x general population; spontaneous full remission rare

Best-intervention remission

Hydroxychloroquine: limited systemic benefit; rituximab: parotid gland improvement and fatigue in some trials but primary endpoint failure in Phase 3 (TEARS, TRACTISS); no disease-modifying therapy approved; best outcomes with early systematic sicca management

Gap size

Very large — no approved disease-modifying therapy; symptomatic management only for glandular features

Primary barrier

biological + access

Sjögren's research has been hampered by heterogeneous disease and lack of validated endpoints; rituximab failed multiple Phase 3 trials despite positive Phase 2 data (endpoint selection problem); anti-Ro/SSA positivity enriches trials but treatment effects still modest; diagnosis itself is delayed 4-7 years on average

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

BTK 254 CD19 40 CD40 26 CD40LG 22 CHRM3 333 IFNAR1 20 MS4A1 28 TNFRSF13C 2 TNFSF13B 8 TYK2 223

BTK

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
PRN694	↓ inhibits	Mechanistic		DGIdb
RN486	↓ inhibits	Mechanistic		DGIdb
PD166285	? unclear	Mechanistic		DGIdb
PTD10	↓ inhibits	Mechanistic		DGIdb
BRANEBRUTINIB	↓ inhibits	Mechanistic		DGIdb
ACALABRUTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 71 [WO2018191577A1]	↓ inhibits	Mechanistic		DGIdb
COMPOUND 25 [PMID: 31260299]	↓ inhibits	Mechanistic		DGIdb
COMPOUND 38 [PMID: 24915291]	↓ inhibits	Mechanistic		DGIdb
IBRUTINIB	↓ inhibits	Mechanistic	0.5 nM (IC50)	DGIdb
ZM447439	? unclear	Mechanistic		DGIdb
BTK INHIBITOR TL-895	? unclear	Mechanistic		DGIdb
ZYBT1	↓ inhibits	Mechanistic		DGIdb
EVOBRUTINIB	↓ inhibits	Mechanistic		DGIdb
FENEBRUTINIB	↓ inhibits	Mechanistic		DGIdb
TOLEBRUTINIB	↓ inhibits	Mechanistic		DGIdb
RILZABRUTINIB	? unclear	Mechanistic		DGIdb
CGI1746	↓ inhibits	Mechanistic		DGIdb
TAMATINIB	? unclear	Mechanistic		DGIdb
ZANUBRUTINIB	↓ inhibits	Mechanistic		DGIdb
ENTRECTINIB	? unclear	Mechanistic	158.49 nM (Ki)	DGIdb
LUXEPTINIB	↓ inhibits	Mechanistic		DGIdb
BTK INHIBITOR 16 [PMID: 30122225]	↓ inhibits	Mechanistic		DGIdb
ZELEBRUDOMIDE	? unclear	Mechanistic		DGIdb
BIIB068	↓ inhibits	Mechanistic		DGIdb
PROTAC 23 [PMID: 38321747]	↓ inhibits	Mechanistic		DGIdb
NVP-TAE684	? unclear	Mechanistic		DGIdb
COMPOUND 36 [PMID: 21958547]	↓ inhibits	Mechanistic		DGIdb
CINSEBRUTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 9 [PMID: 26006010]	↓ inhibits	Mechanistic		DGIdb
DASATINIB ANHYDROUS	? unclear	Mechanistic		DGIdb
NEMTABRUTINIB	? unclear	Mechanistic		DGIdb
JNJ-64264681	↓ inhibits	Mechanistic		DGIdb
SPEBRUTINIB	↓ inhibits	Mechanistic		DGIdb
CHEMBL:CHEMBL1997335	? unclear	Mechanistic		DGIdb
RITLECITINIB	↓ inhibits	Mechanistic		DGIdb
BIRELENTINIB	↓ inhibits	Mechanistic		DGIdb
PF-562271	? unclear	Mechanistic		DGIdb
ORELABRUTINIB	↓ inhibits	Mechanistic		DGIdb
MIDOBRUTINIB	↓ inhibits	Mechanistic		DGIdb

Showing top 40 of 254 agents ranked by evidence tier.

CD19

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
AUTOLOGOUS ANTI-CD19 CAR T-CELLS IM19	? unclear	Mechanistic	DGIdb
BLINATUMOMAB	? unclear	Mechanistic	DGIdb
LONCASTUXIMAB TESIRINE	~ modulates	Mechanistic	DGIdb
AUTOLOGOUS CD19CAR-CD28-CD137/CD27/CD3ZETA-ICASP9-EXPRESSING T-LYMPHOCYTES	? unclear	Mechanistic	DGIdb
TISAGENLECLEUCEL	? unclear	Mechanistic	DGIdb
AUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS C-CAR011	? unclear	Mechanistic	DGIdb
VADACABTAGENE LERALEUCEL	? unclear	Mechanistic	DGIdb
LISOCABTAGENE MARALEUCEL	? unclear	Mechanistic	DGIdb
AUTOLOGOUS ANTI-CD19CAR-4-1BB-CD3ZETA-EGFRT-EXPRESSING T LYMPHOCYTES	? unclear	Mechanistic	DGIdb
MDX-1342	~ modulates	Mechanistic	DGIdb
AXICABTAGENE CILOLEUCEL	? unclear	Mechanistic	DGIdb
ANTI-CD19 CAR T CELLS PREPARATION	? unclear	Mechanistic	DGIdb
INEBILIZUMAB	? unclear	Mechanistic	DGIdb
ALLOGENEIC ANTI-CD19-CAR-CD28-IL-15-EXPRESSING NATURAL KILLER T-CELLS	? unclear	Mechanistic	DGIdb
AZERCABTAGENE ZAPRELEUCEL	? unclear	Mechanistic	DGIdb
TAFASITAMAB	? unclear	Mechanistic	DGIdb
DENINTUZUMAB MAFODOTIN	~ modulates	Mechanistic	DGIdb
COLTUXIMAB RAVTANSINE	? unclear	Mechanistic	DGIdb
OBEXELIMAB	↓ inhibits	Mechanistic	DGIdb
AMG-729	~ modulates	Mechanistic	DGIdb
CD19CAR-CD3ZETA-4-1BB-EXPRESSING ALLOGENEIC T-LYMPHOCYTE CELLS	? unclear	Mechanistic	DGIdb
AUTOLOGOUS ANTI-CD19 CAR-T CELLS TBI-1501	? unclear	Mechanistic	DGIdb
AUTOLOGOUS CD19 CAR-EXPRESSING CD4+/CD8+ T-CELLS MB-CART19.1	? unclear	Mechanistic	DGIdb
AFM-11	? unclear	Mechanistic	DGIdb
BREXUCABTAGENE AUTOLEUCEL	~ modulates	Mechanistic	DGIdb
TAPLITUMOMAB PAPTOX	~ modulates	Mechanistic	DGIdb
ANTI-CD19 CAR T-CELLS XLCART001	? unclear	Mechanistic	DGIdb
AUTOLOGOUS ANTI-CD19 CAR-EXPRESSING T-LYMPHOCYTES CLIC-1901	? unclear	Mechanistic	DGIdb
DENINTUZUMAB	~ modulates	Mechanistic	DGIdb
AUTO3	? unclear	Mechanistic	DGIdb
DEGLYCOSYLATED RICIN A CHAIN-CONJUGATED ANTI-CD19/ANTI-CD22 IMMUNOTOXINS	? unclear	Mechanistic	DGIdb
DUVORTUXIZUMAB	? unclear	Mechanistic	DGIdb
ANTI-CD19 CAR-T CELLS	? unclear	Mechanistic	DGIdb
AUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS SJCAR19	? unclear	Mechanistic	DGIdb
ONCOLYSIN B	~ modulates	Mechanistic	DGIdb
ANTI-CD20 CAR T CELLS PREPARATION	? unclear	Mechanistic	DGIdb
CD19-TARGETED CAR T2 CELLS	? unclear	Mechanistic	DGIdb
OBECABTAGENE AUTOLEUCEL	~ modulates	Mechanistic	DGIdb
JCAR014	? unclear	Mechanistic	DGIdb
RELMACABTAGENE AUTOLEUCEL	? unclear	Mechanistic	DGIdb

CD40

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
PG-102	↓ inhibits	Mechanistic		DGIdb
MANNOSE-BINDING LECTIN	? unclear	Mechanistic		DGIdb
MONOCLONAL ANTIBODY SGN-14	? unclear	Mechanistic		DGIdb
DACETUZUMAB	? unclear	Mechanistic		DGIdb
TENELIXIMAB	↑ activates	Mechanistic		DGIdb
STREPTOZOCIN	? unclear	Mechanistic		DGIdb
ALDESLEUKIN	? unclear	Mechanistic		DGIdb
PREDNISOLONE	? unclear	Mechanistic		DGIdb
RAVAGALIMAB	? unclear	Mechanistic		DGIdb
SELICRELUMAB	↑ activates	Mechanistic		DGIdb
FLUDARABINE	? unclear	Mechanistic		DGIdb
CD40 LIGAND	↑ activates	Mechanistic		DGIdb
AUTOLOGOUS PROSTATE CANCER ANTIGEN-EXPRESSING DENDRITIC CELL VACCINE BPX-101	? unclear	Mechanistic		DGIdb
MITAZALIMAB	? unclear	Mechanistic		DGIdb
GILORALIMAB	↑ activates	Mechanistic		DGIdb
TETANUS TOXOID VACCINE	? unclear	Mechanistic		DGIdb
ISCALIMAB	↓ inhibits	Mechanistic		DGIdb
SOTIGALIMAB	↑ activates	Mechanistic		DGIdb
BLESELUMAB	↓ inhibits	Mechanistic		DGIdb
RECOMBINANT CD40-LIGAND	? unclear	Mechanistic		DGIdb
LUCATUMUMAB	↓ inhibits	Mechanistic		DGIdb
HYDROQUINONE	? unclear	Mechanistic		DGIdb
CDX-1140	↑ activates	Mechanistic		DGIdb
CHEMBL1241017	↓ inhibits	Mechanistic	78.0 nM (IC50)	ChEMBL
CHEMBL1241018	↓ inhibits	Mechanistic	50.0 nM (IC50)	ChEMBL
CHEMBL1241019	↓ inhibits	Mechanistic	9900.0 nM (IC50)	ChEMBL

CD40LG

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
ATORVASTATIN CALCIUM TRIHYDRATE	? unclear	Mechanistic	DGIdb
DAPIROLIZUMAB PEGOL	↓ inhibits	Mechanistic	DGIdb
ROSIGLITAZONE MALEATE	? unclear	Mechanistic	DGIdb
RECOMBINANT INTERLEUKIN-2	? unclear	Mechanistic	DGIdb
ALPROSTADIL	? unclear	Mechanistic	DGIdb
ANTI-CD40 MONOCLONAL ANTIBODY CHI LOB 7/4	? unclear	Mechanistic	DGIdb
ANTINEOPLASTIC VACCINE	? unclear	Mechanistic	DGIdb
MUROMONAB-CD3	? unclear	Mechanistic	DGIdb
DAZODALIBEP	? unclear	Mechanistic	DGIdb
TORALIZUMAB	↓ inhibits	Mechanistic	DGIdb
ADALIMUMAB	? unclear	Mechanistic	DGIdb
RUPLIZUMAB	↓ inhibits	Mechanistic	DGIdb
TEGOPRUBART	↓ inhibits	Mechanistic	DGIdb
RAVAGALIMAB	↓ inhibits	Mechanistic	DGIdb
SELICRELUMAB	? unclear	Mechanistic	DGIdb
PG-102	? unclear	Mechanistic	DGIdb
FENOFIBRATE MICRONIZED	? unclear	Mechanistic	DGIdb
BISPECIFIC ANTIBODY	? unclear	Mechanistic	DGIdb
AUTOLOGOUS PROSTATE CANCER ANTIGEN-EXPRESSING DENDRITIC CELL VACCINE BPX-101	? unclear	Mechanistic	DGIdb
ANTI-CD40/ANTI-MESOTHELIN BISPECIFIC ANTIBODY ABBV-428	? unclear	Mechanistic	DGIdb
IMATINIB	? unclear	Mechanistic	DGIdb
LUCATUMUMAB	? unclear	Mechanistic	DGIdb

CHRM3

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
OCTOTROPINE METHYLBROMIDE	↓ inhibits	Mechanistic		DGIdb
TIOTROPIUM	↓ inhibits	Mechanistic		DGIdb
BETHANECHOL CHLORIDE	↑ activates	Mechanistic		DGIdb
GLYCOPYRRONIUM TOSYLATE	↓ inhibits	Mechanistic		DGIdb
REVEFENACIN	↓ inhibits	Mechanistic		DGIdb
OXYBUTYNIN	↓ inhibits	Mechanistic		DGIdb
MUSCARINIC TOXIN 7	↓ inhibits	Mechanistic		DGIdb
SOLIFENACIN	↓ inhibits	Mechanistic		DGIdb
ZAMIFENACIN	? unclear	Mechanistic		DGIdb
UMECLIDINIUM BROMIDE	↓ inhibits	Mechanistic		DGIdb
ACLIDINIUM	↓ inhibits	Mechanistic		DGIdb
PROPIOMAZINE	? unclear	Mechanistic		DGIdb
(S)-DIMETINDENE	↓ inhibits	Mechanistic		DGIdb
TERODILINE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
IPRATROPIUM CATION	↓ inhibits	Mechanistic		DGIdb
PENTYLTHIO-TZTP	↑ activates	Mechanistic		DGIdb
CARBAMOYLCHOLINE	↑ activates	Mechanistic		DGIdb
IPRATROPIUM BROMIDE	↓ inhibits	Mechanistic		DGIdb
DIPHENIDOL	? unclear	Mechanistic		DGIdb
METHYLHOMATROPINE	? unclear	Mechanistic		DGIdb
PROMAZINE	? unclear	Mechanistic		DGIdb
METHSCOPOLAMINE BROMIDE	↓ inhibits	Mechanistic		DGIdb
ACETYLCHOLINE CHLORIDE	↑ activates	Mechanistic		DGIdb
TROPICAMIDE	↓ inhibits	Mechanistic		DGIdb
AZD8683	↓ inhibits	Mechanistic		DGIdb
PIPERTRAMINE	? unclear	Mechanistic		DGIdb
TRIDIHEXETHYL	? unclear	Mechanistic		DGIdb
MEPENZOLATE BROMIDE	↓ inhibits	Mechanistic		DGIdb
TOLTERODINE	↓ inhibits	Mechanistic		DGIdb
FESOTERODINE	? unclear	Mechanistic		DGIdb
HEXOCYCLIUM METHYLSULFATE	↓ inhibits	Mechanistic		DGIdb
SUCCINYLCHOLINE	? unclear	Mechanistic		DGIdb
OLANZAPINE	? unclear	Mechanistic		DGIdb
SOFPIRONIUM BROMIDE	↓ inhibits	Mechanistic		DGIdb
[3H]TIOTROPIUM	↓ inhibits	Mechanistic		DGIdb
ML381	↓ inhibits	Mechanistic		DGIdb
PIPERTRAMINE AMIDE	? unclear	Mechanistic		DGIdb
MEPENZOLATE	↓ inhibits	Mechanistic		DGIdb
ACECLIDINE	↑ activates	Mechanistic		DGIdb
OXOTREMORINE	↑ activates	Mechanistic	210.0 nM (EC50)	DGIdb

Showing top 40 of 333 agents ranked by evidence tier.

IFNAR1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
INTERFERON ALFA-N3	↑ activates	Mechanistic		DGIdb
INTERFERON BETA-1A	↑ activates	Mechanistic		DGIdb
INTERFERON ALFA-N1	? unclear	Mechanistic		DGIdb
ANIFROLUMAB	? unclear	Mechanistic		DGIdb
INTERFERON BETA	? unclear	Mechanistic		DGIdb
PEGINTERFERON ALFA-2A	↑ activates	Mechanistic		DGIdb
PEGINTERFERON BETA-1A	↑ activates	Mechanistic		DGIdb
INTERFERON ALFA-2A	↑ activates	Mechanistic		DGIdb
SIFALIMUMAB	? unclear	Mechanistic		DGIdb
INTERFERON-ALPHA	? unclear	Mechanistic		DGIdb
INTERFERON ALFACON-1	↑ activates	Mechanistic		DGIdb
IFN-&BETA;	↑ activates	Mechanistic		DGIdb
ALBINTERFERON ALFA-2B	↑ activates	Mechanistic		DGIdb
PEGINTERFERON ALFACON-1	? unclear	Mechanistic		DGIdb
GLATIRAMER	? unclear	Mechanistic		DGIdb
INTERFERON BETA-1B	↑ activates	Mechanistic		DGIdb
PEGINTERFERON ALFA-2B	↑ activates	Mechanistic		DGIdb
INTERFERON ALFA-2B	↑ activates	Mechanistic		DGIdb
ROPEGINTERFERON ALFA-2B	~ modulates	Mechanistic		DGIdb
CHEMBL1617534	↓ inhibits	Mechanistic	4000.0 nM (Kd)	ChEMBL

MS4A1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
RITUXIMAB	~ modulates	Mechanistic	DGIdb
UBLITUXIMAB	~ modulates	Mechanistic	DGIdb
VELTUZUMAB	? unclear	Mechanistic	DGIdb
OFATUMUMAB	~ modulates	Mechanistic	DGIdb
OBINUTUZUMAB	~ modulates	Mechanistic	DGIdb
OCARATUZUMAB	~ modulates	Mechanistic	DGIdb
TOSITUMOMAB	~ modulates	Mechanistic	DGIdb
TISAGENLECLEUCEL	? unclear	Mechanistic	DGIdb
IODINE-131-TOSITUMOMAB	? unclear	Mechanistic	DGIdb
EPCORITAMAB	? unclear	Mechanistic	DGIdb
GLOFITAMAB	~ modulates	Mechanistic	DGIdb
TRU-015	~ modulates	Mechanistic	DGIdb
ODRONEXTAMAB	? unclear	Mechanistic	DGIdb
OCRELIZUMAB	~ modulates	Mechanistic	DGIdb
ANTI-CD20 CAR T CELLS PREPARATION	? unclear	Mechanistic	DGIdb
DI-LEU16-IL2	? unclear	Mechanistic	DGIdb
MONOCLONAL ANTIBODY 1F5	? unclear	Mechanistic	DGIdb
MT-3724	~ modulates	Mechanistic	DGIdb
MOSUNETUZUMAB	? unclear	Mechanistic	DGIdb
PLAMOTAMAB	? unclear	Mechanistic	DGIdb
AUTOLOGOUS ANTI-CD20 CAR TRANSDUCED CD4/CD8 ENRICHED T-CELLS MB-CART20.1	? unclear	Mechanistic	DGIdb
FBT-A05	~ modulates	Mechanistic	DGIdb
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN	~ modulates	Mechanistic	DGIdb
BSAB (CD89-CD20)	? unclear	Mechanistic	DGIdb
LFB-R603	~ modulates	Mechanistic	DGIdb
DIVOZILIMAB	? unclear	Mechanistic	DGIdb
IBRITUMOMAB TIUXETAN	? unclear	Mechanistic	DGIdb
TOSITUMOMAB 131I	~ modulates	Mechanistic	DGIdb

TNFRSF13C

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
IANALUMAB	? unclear	Mechanistic		DGIdb
BAFF	? unclear	Mechanistic		DGIdb

TNFSF13B

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
BLISIBIMOD	? unclear	Mechanistic	DGIdb
ETOPOSIDE	? unclear	Mechanistic	DGIdb
ATACICEPT	↓ inhibits	Mechanistic	DGIdb
TABALUMAB	↓ inhibits	Mechanistic	DGIdb
BRIOBACEPT	↓ inhibits	Mechanistic	DGIdb
TIBULIZUMAB	↓ inhibits	Mechanistic	DGIdb
BELIMUMAB	↓ inhibits	Mechanistic	DGIdb
ROZIBAFUSP ALFA	↓ inhibits	Mechanistic	DGIdb

TYK2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
JAK3 INHIBITOR 34	↓ inhibits	Mechanistic		DGIdb
SDC-1801	↓ inhibits	Mechanistic		DGIdb
TOFACITINIB	↓ inhibits	Mechanistic	250.0 nM (Kd)	DGIdb
GOLIDOCITINIB	↓ inhibits	Mechanistic		DGIdb
TYK2 INHIBITOR 18 [WO2023227946]	~ modulates	Mechanistic		DGIdb
GDC-0214	↓ inhibits	Mechanistic		DGIdb
TAMATINIB	? unclear	Mechanistic		DGIdb
JAK INHIBITOR 20A	↓ inhibits	Mechanistic		DGIdb
NVP-TAE684	? unclear	Mechanistic		DGIdb
PEFICITINIB	↓ inhibits	Mechanistic		DGIdb
TYD-68	? unclear	Mechanistic		DGIdb
BREPOCITINIB	↓ inhibits	Mechanistic		DGIdb
LORPUCITINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 25AP [PMID: 37796543]	↓ inhibits	Mechanistic		DGIdb
TOZASERTIB	? unclear	Mechanistic	510.0 nM (Kd)	DGIdb
FILGOTINIB MALEATE	↓ inhibits	Mechanistic		DGIdb
DEURUXOLITINIB PHOSPHATE	↓ inhibits	Mechanistic		DGIdb
MOMELOTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 13 [PMID: 34333981]	↓ inhibits	Mechanistic		DGIdb
DEUCRAVACITINIB	~ modulates	Mechanistic		DGIdb
CADEFRECITINIB	↓ inhibits	Mechanistic		DGIdb
RUXOLITINIB	↓ inhibits	Mechanistic	19.0 nM (IC50)	DGIdb
JNJ-7706621	? unclear	Mechanistic	32.0 nM (Kd)	DGIdb
BMS-986202	↓ inhibits	Mechanistic		DGIdb
FILGOTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 30 [PMID: 37057760]	↓ inhibits	Mechanistic		DGIdb
SJ988497	? unclear	Mechanistic		DGIdb
RECOMBINANT INTERLEUKIN-2	? unclear	Mechanistic		DGIdb
CERDULATINIB	↓ inhibits	Mechanistic		DGIdb
EDODEKIN ALFA	? unclear	Mechanistic		DGIdb
RG-1530	? unclear	Mechanistic		DGIdb
FEDRATINIB	↓ inhibits	Mechanistic	150.0 nM (IC50)	DGIdb
UPADACITINIB	↓ inhibits	Mechanistic		DGIdb
SAR-20347	↓ inhibits	Mechanistic		DGIdb
ZOTIRACICLIB	↓ inhibits	Mechanistic		DGIdb
G&OUML; 6976	? unclear	Mechanistic		DGIdb
COMPOUND 13AC [PMID: 33256400]	↓ inhibits	Mechanistic		DGIdb
TYK2 INHIBITOR 14L	↓ inhibits	Mechanistic		DGIdb
OCLACITINIB	↓ inhibits	Mechanistic		DGIdb
ILORASERTIB	? unclear	Mechanistic		DGIdb

Showing top 40 of 223 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Sjögren's Syndrome: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE Recruiting

NCT07118241 Phase: 2 Started: 2025-09-17

rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity Active Not Recruiting

NCT06979531 Phase: 2 Started: 2025-06-30

This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome Completed

NCT04078386 Phase: 2 Started: 2019-11-21

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Primary Sjögren's Syndrome.

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) Recruiting

NCT06747949 Phase: 3 Started: 2025-02-25

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome Active Not Recruiting

NCT05946941 Phase: 3 Started: 2023-09-11

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome Completed

NCT06203457 Phase: 2 Started: 2023-11-29

Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS). This open-label extension study will evaluate the long-term safety of efgartigimod in participants with SjD who have completed the treatment period of the quali...

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Active Not Recruiting

NCT06245408 Phase: 3 Started: 2024-04-08

Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS. 2. To evaluate the effect of d...

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) Completed

NCT04572841 Phase: 2 Started: 2020-11-12

Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) Se...

Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome Completed

NCT06484855 Phase: 1 Started: 2024-07-14

This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IBI355 in primary Sjogren's syndrome (pSS) patients. This study also aims to evaluate the anti-Drug antibody after multiple ascending doses of IBI355 in pSS patients.

Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies Completed

NCT03700138 Phase: 3 Started: 2019-06-19

To summarise, the peripheral neurological complications experienced by patients with primary Sjögren's syndrome are particularly bothersome since they are common and often result in significant disability related to pain or motor impairment. There is currently no standard treatment for these patient...

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) Completed

NCT05817669 Phase: 2 Started: 2023-04-04

The purpose of this study is to assess the efficacy and safety of human FcRn blocking therapy with efgartigimod compared to placebo, in participants with pSS.

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome Completed

NCT04129164 Phase: 2 Started: 2019-12-09

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

New Clinical End-points in Patients With Primary Sjögren's Syndrome Recruiting

NCT05113004 Phase: 2 Started: 2022-01-20

There are no approved treatments for pSS and the clinical endpoints currently used in clinical trials are inadequate to capture all aspects of the disease that should be evaluated in clinical trials. The newly developed composite endpoint: Sjögren's Tool for Assessing Response to treatment (STAR) wi...

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome Recruiting

NCT04981145 Phase: 4 Started: 2022-01-14

A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome Completed

NCT05605665 Phase: 1/2 Started: 2022-12-05

The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of low-dose IL-2 combined with rapamycin in the treatment of Sjogren's syndrome

Agents Found By Disease-Level Search

Searched directly from “Sjögren's Syndrome” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

42 agents shown (approved or with trial evidence) — 39 not found by the gene-target search above.

HydroxychloroquineNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00873496 NCT01601028 NCT00632866

KCT-0809 ophthalmic solutionNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02503189 NCT02503163

ianalumab (VAY736)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02149420 NCT07621809

Belimumab

· 2 trials · source: ClinicalTrials.gov
NCT01160666 NCT02631538

CFZ533 active -Cohort 3NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02291029 NCT02291029

Dazodalibep

· 2 trials · source: ClinicalTrials.gov
NCT06104124 NCT06747949

LimphoStat-BNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01008982

UstekinumabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04093531

Omega 3 fatty acidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05005806

Recombinant Human Proteoglycan 4NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07118241

dexa, hand grip strength, myostatin, follistatinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07804719

IBI355NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06484855

MSCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06805448

dazodalibep (VIB4920)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04129164

Impression CytologyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04493658

low-dose interleukin-2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05605665

rapamycinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05605665

TCM (Gan-Lu-Yin)GLYNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04111341

ASCsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04615455

Cryostor CS10NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04615455

Autologous CD19-BCMA Dual-Target CAR T-Cell TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07361094

Abatacept SCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02067910

SibeprenlimabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06928142

RSLV-132NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06440525

Ocular Surface Disease Index (OSDI)NOT in gene-target list